Nuvilex Inc. (NASDAQ:PMCB – Get Free Report)’s stock price passed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $0.40 and traded as low as $0.2469. Nuvilex shares last traded at $0.3990, with a volume of 1,268,048 shares traded.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.
Read Our Latest Report on Nuvilex
Nuvilex Stock Down 12.5%
Nuvilex (NASDAQ:PMCB – Get Free Report) last announced its earnings results on Monday, September 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.48).
About Nuvilex
Nuvilex, Inc. was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc. and continued to trade under the ticker symbol PMCB. The company focused on developing cellular therapies intended to treat serious diseases, particularly cancer and diabetes. Its primary technology involved encapsulating genetically engineered human cells in proprietary cellulose-based capsules. These cells were designed to produce therapeutic substances inside the body while limiting exposure to healthy tissue.
Further Reading
- Five stocks we like better than Nuvilex
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
